| 何 园,宁 宁,王巧鸽,赵 璐,赵海燕.血清载脂蛋白AI、鳞状细胞癌抗原与子宫内膜癌病理特征的关系及对淋巴结转移的预测研究[J].现代生物医学进展英文版,2023,(13):2558-2562. |
| 血清载脂蛋白AI、鳞状细胞癌抗原与子宫内膜癌病理特征的关系及对淋巴结转移的预测研究 |
| The Relationship between Serum Apolipoprotein AI, Squamous Cell Carcinoma Antigen and Pathological Features of Endometrial Carcinoma and the Prediction of Lymph Node Metastasis |
| Received:December 05, 2022 Revised:December 28, 2022 |
| DOI：10.13241/j.cnki.pmb.2023.13.032 |
| 中文关键词: 子宫内膜癌 载脂蛋白AI 鳞状细胞癌抗原 病理特征 淋巴结转移 |
| 英文关键词: Endometrial carcinoma Apolipoprotein AI Squamous cell carcinoma antigen Pathological features Lymph node metastasis |
| 基金项目:陕西省重点研发计划项目（2018SF-068） |
|
| Hits: 511 |
| Download times: 346 |
| 中文摘要: |
| 摘要 目的：分析血清载脂蛋白AI、鳞状细胞癌抗原与子宫内膜癌病理特征的关系及对淋巴结转移的预测价值。方法：选择我院自2020年7月至2022年7月收治的156例行手术治疗的子宫内膜癌患者作为研究对象，检测血清载脂蛋白AI、鳞状细胞癌抗原表达水平，分析不同临床分期、病理分级、子宫肌层浸润程度的子宫内膜癌血清载脂蛋白AI、鳞状细胞癌抗原表达水平的差异性，比较淋巴结转移组与非淋巴结转移组血清载脂蛋白AI、鳞状细胞癌抗原表达水平，通过受试者工作特征曲线（ROC）下面积（AUC）评价血清载脂蛋白AI联合鳞状细胞癌抗原对子宫内膜癌患者发生淋巴结转移的预测价值。结果：Ⅲ～Ⅳ期组血清载脂蛋白AI低于Ⅰ～Ⅱ期组，鳞状细胞癌抗原表达水平高于Ⅰ～Ⅱ期组（P＜0.05）；中低分化组血清载脂蛋白AI水平低于高分化组，鳞状细胞癌抗原表达水平高于高分化组（P＜0.05）；子宫肌层浸润≥1/2组血清载脂蛋白AI水平低于子宫肌层浸润＜1/2组，鳞状细胞癌抗原表达水平高于子宫肌层浸润＜1/2组（P＜0.05）；在120例子宫内膜癌患者中，发生淋巴结转移28例；淋巴结转移组血清载脂蛋白AI低于非淋巴结转移组，鳞状细胞癌抗原表达水平高于非淋巴结转移组（P＜0.05）；经ROC曲线分析，血清载脂蛋白AI联合鳞状细胞癌抗原预测子宫内膜癌患者发生淋巴结转移的AUC为0.910。结论：血清载脂蛋白AI、鳞状细胞癌抗原与子宫内膜癌的不同临床分期、病理分级、子宫肌层浸润程度有关，术前检测两者表达水平有助于淋巴结转移的预测，对于指导临床治疗具有积极作用。 |
| 英文摘要: |
| ABSTRACT Objective: To analyze the relationship between serum apolipoprotein AI, squamous cell carcinoma antigen and pathological features of endometrial carcinoma and their predictive value for lymph node metastasis. Methods: A total of 156 patients with endometrial cancer who underwent surgical treatment in our hospital from July 2020 to July 2022 were selected as subjects. The expression levels of serum apolipoprotein AI and squamous cell carcinoma antigen were detected. To analyze the differences in the expression levels of serum apolipoprotein AI and squamous cell carcinoma antigen in endometrial carcinoma with different clinical stages,pathological grades and degree of myometrium infiltration, and compare the expression levels of serum apolipoprotein AI and squamous cell carcinoma antigen between the lymph node metastasis group and the non-lymph node metastasis group. The predictive value of serum apolipoprotein AI combined with squamous cell carcinoma antigen for lymph node metastasis in patients with endometrial cancer was evaluated by area under receiver operating characteristic curve (ROC) (AUC). Results: The serum APolipoprotein AI in groups Ⅲ to Ⅳ was lower than that in groups Ⅰ to Ⅱ, and the expression level of squamous cell carcinoma antigen was higher than that in groups Ⅰ to Ⅱ(P<0.05). The serum APolipoprotein AI level in the medium-low differentiation group was lower than that in the highly differentiated group, and the squamous cell carcinoma antigen expression level was higher than that in the highly differentiated group(P<0.05). The serum apolipoprotein AI level in myometrium infiltration ≥1/2 group was lower than that in myometrium infiltration<1/2 group,and the expression level of squamous cell carcinoma antigen was higher than that in myometrium infiltration<1/2 group(P<0.05). Among 120 patients with endometrial carcinoma, 28 had lymph node metastasis. Serum APolipoprotein AI in lymph node metastasis group was lower than that in non-lymph node metastasis group, and the expression level of squamous cell carcinoma antigen was higher than that in non-lymph node metastasis group(P<0.05). ROC curve analysis showed that the AUC of serum apolipoprotein AI combined with squamous cell carcinoma antigen predicted lymph node metastasis in patients with endometrial cancer was 0.910. Conclusion: Serum APolipoprotein AI and squamous cell carcinoma antigen are related to different clinical stages, pathological grades and degree of myometrium infiltration of endometrial carcinoma. Preoperative detection of both expression levels is helpful for the prediction of lymph node metastasis and has a positive role in guiding clinical treatment. |
|
View Full Text
View/Add Comment Download reader |
| Close |
